Search Results

There are 901 results for: content related to: Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

  1. You have free access to this content
    JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2

    Hepatology Research

    Volume 46, Issue 2, February 2016, Pages: 129–165, Yasuhiro Asahina, Namiki Izumi, Kumada Hiromitsu, Masayuki Kurosaki, Kazuhiko Koike, Fumitaka Suzuki, Hajime Takikawa, Atsushi Tanaka, Eiji Tanaka, Yasuhito Tanaka, Hirohito Tsubouchi, Norio Hayashi, Naoki Hiramatsu and Hiroshi Yotsuyanagi

    Version of Record online : 15 FEB 2016, DOI: 10.1111/hepr.12645

  2. You have free access to this content
    Poster Session 2: Hepatitis C: Therapeutics (Approved Agents)

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 714A–807A,

    Version of Record online : 7 OCT 2015, DOI: 10.1002/hep.28228

  3. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy

    Journal of Medical Virology

    Volume 87, Issue 11, November 2015, Pages: 1913–1920, Satoshi Yoshimi, Michio Imamura, Eisuke Murakami, Nobuhiko Hiraga, Masataka Tsuge, Yoshiiku Kawakami, Hiroshi Aikata, Hiromi Abe, C. Nelson Hayes, Tamito Sasaki, Hidenori Ochi and Kazuaki Chayama

    Version of Record online : 16 JUN 2015, DOI: 10.1002/jmv.24255

  4. You have free access to this content
    Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection

    Alimentary Pharmacology & Therapeutics

    Volume 42, Issue 3, August 2015, Pages: 258–272, C. Bunchorntavakul and K. R. Reddy

    Version of Record online : 27 MAY 2015, DOI: 10.1111/apt.13264

  5. You have free access to this content
    Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

    Hepatology

    Volume 58, Issue 3, September 2013, Pages: 902–911, Fiona McPhee, Dennis Hernandez, Fei Yu, Joseph Ueland, Aaron Monikowski, Arlene Carifa, Paul Falk, Chunfu Wang, Robert Fridell, Timothy Eley, Nannan Zhou and David Gardiner

    Version of Record online : 16 JUL 2013, DOI: 10.1002/hep.26388

  6. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report

    Hepatology Research

    Volume 46, Issue 7, June 2016, Pages: 707–712, Tomokazu Kawaoka, Michio Imamura, Kei Morio, Yuki Nakamura, Masataka Tsuge, C. Nelson Hayes, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Kouhei Ishiyama, Kentaro Ide, Hirotaka Tashiro, Hideki Ohdan and Kazuaki Chayama

    Version of Record online : 2 NOV 2015, DOI: 10.1111/hepr.12602

  7. You have free access to this content
    Poster Sessions

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 93A–207A,

    Version of Record online : 1 OCT 2015, DOI: 10.1002/hep.28162

  8. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals

    Journal of Medical Virology

    Volume 88, Issue 10, October 2016, Pages: 1659–1671, Nicola Coppola, Carmine Minichini, Mario Starace, Caterina Sagnelli and Evangelista Sagnelli

    Version of Record online : 29 MAR 2016, DOI: 10.1002/jmv.24527

  9. Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism

    Hepatology Research

    Volume 46, Issue 12, November 2016, Pages: 1234–1246, Yoshihito Uchida, Jun-ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Mie Inao, Yukinori Imai, Nobuaki Nakayama and Satoshi Mochida

    Version of Record online : 30 MAR 2016, DOI: 10.1111/hepr.12673

  10. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

    Journal of Medical Virology

    Volume 88, Issue 3, March 2016, Pages: 506–511, Norio Akuta, Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda and Hiromitsu Kumada

    Version of Record online : 27 AUG 2015, DOI: 10.1002/jmv.24360

  11. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction

    Journal of Medical Virology

    Volume 89, Issue 4, April 2017, Pages: 665–671, Yuki Nakamura, Michio Imamura, Yoshiiku Kawakami, Yuji Teraoka, Kana Daijo, Fumi Honda, Kei Morio, Tomoki Kobayashi, Takashi Nakahara, Yuko Nagaoki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Hiroshi Aikata, C. Nelson Hayes, Daiki Miki, Hidenori Ochi and Kazuaki Chayama

    Version of Record online : 24 OCT 2016, DOI: 10.1002/jmv.24679

  12. You have free access to this content
    Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor

    Journal of Pharmaceutical Sciences

    Volume 104, Issue 9, September 2015, Pages: 2813–2823, Kathleen W. Mosure, Jay O. Knipe, Marc Browning, Vinod Arora, Yue-Zhong Shu, Thomas Phillip, Fiona Mcphee, Paul Scola, Anand Balakrishnan, Matthew G. Soars, Kenneth Santone and Michael Sinz

    Version of Record online : 28 JAN 2015, DOI: 10.1002/jps.24356

  13. You have free access to this content
    Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis

    Hepatology Research

    Volume 47, Issue 3, March 2017, Pages: E120–E131, Eiichi Ogawa, Norihiro Furusyo, Naoki Yamashita, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Makoto Nakamuta, Takeaki Satoh, Hideyuki Nomura, Koichi Azuma, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi and The Kyushu University Liver Disease Study(KULDS) Group

    Version of Record online : 10 JUN 2016, DOI: 10.1111/hepr.12738

  14. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients

    Journal of Gastroenterology and Hepatology

    Volume 32, Issue 3, March 2017, Pages: 645–650, Kei Morio, Michio Imamura, Yoshiiku Kawakami, Reona Morio, Tomoki Kobayashi, Satoe Yokoyama, Yuko Nagaoki, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Grace Naswa Makokha, C Nelson Hayes, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yoji Honda, Nami Mori, Shintaro Takaki, Keiji Tsuji and Kazuaki Chayama

    Version of Record online : 20 MAR 2017, DOI: 10.1111/jgh.13511

  15. You have free access to this content
    Poster Session IV (Abstracts 1638 – 2112)

    Hepatology

    Volume 64, Issue S1, October 2016, Pages: 811–1050,

    Version of Record online : 1 OCT 2016, DOI: 10.1002/hep.28800

  16. You have free access to this content
    Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection

    Hepatology Research

    Volume 44, Issue 14, December 2014, Pages: E360–E367, Mika Miura, Shinya Maekawa, Mitsuaki Sato, Nobutoshi Komatsu, Akihisa Tatsumi, Shinichi Takano, Fumitake Amemiya, Yasuhiro Nakayama, Taisuke Inoue, Minoru Sakamoto and Nobuyuki Enomoto

    Version of Record online : 10 APR 2014, DOI: 10.1111/hepr.12316

  17. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis

    Therapeutic Apheresis and Dialysis

    Volume 20, Issue 5, October 2016, Pages: 462–467, Ryoichi Miyazaki and Kyoko Miyagi

    Version of Record online : 21 APR 2016, DOI: 10.1111/1744-9987.12407

  18. Current prospects for interferon-free treatment of hepatitis C in 2012

    Journal of Gastroenterology and Hepatology

    Volume 28, Issue 1, January 2013, Pages: 38–45, Catherine AM Stedman

    Version of Record online : 19 DEC 2012, DOI: 10.1111/jgh.12028

  19. You have free access to this content
    Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older

    Journal of Medical Virology

    Volume 89, Issue 1, January 2017, Pages: 91–98, Norio Akuta, Hitomi Sezaki, Fumitaka Suzuki, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda and Hiromitsu Kumada

    Version of Record online : 8 JUN 2016, DOI: 10.1002/jmv.24592

  20. You have free access to this content
    Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy

    Alimentary Pharmacology & Therapeutics

    Volume 43, Issue 6, March 2016, Pages: 674–696, D. Banerjee and K. R. Reddy

    Version of Record online : 20 JAN 2016, DOI: 10.1111/apt.13514